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Nigeria has a high burden of hepatitis B virus (HBV) infection, commonly acquired through
vertical transmission. However, there is a lack of an efficient surveillance system for moni-
toring and understanding the epidemiology of HBV among pregnant women. Building on a
previous review on the prevalence of HBV in Nigeria (2000–2013), we conducted a system-
atic review and meta-analysis of HBV prevalence among pregnant women in Nigeria.
Methods
Four electronic databases PubMed, Embase, Global Health, and Scopus were systemati-
cally searched from January 2014 to February 2021. We also searched the African Journal
Online and manually scanned the reference lists of the identified studies for potentially eligi-
ble articles. Observational studies that reported the prevalence of HBsAg and/or HBeAg
among pregnant women in peer-reviewed journals were included in the study. We per-
formed a meta-analysis using a random-effects model. We defined HBV infection as a posi-
tive test to HBsAg.
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Results
From the 158 studies identified, 20 studies with a total sample size of 26, 548 were included
in the meta-analysis. The pooled prevalence of HBV infection among pregnant women
across the studies was 6.49% (95% confidence interval [CI] = 4.75–8.46%; I2 = 96.7%, p =
0.001; n = 20). The prevalence of HBV was significantly lower among pregnant women with
at least secondary education compared with those with no education or primary education
(prevalence ratio = 0.7, 95% CI = 0.58–0.87; n = 10). However, the prevalence of HBV was
not significantly different by age, religion, marital status, or tribe. The prevalence of HBV
was not significantly different among pregnant women with previous surgery, blood transfu-
sion, multiple lifetime sex partners, tribal marks, tattoos, scarification, or sexually transmitted
infections, compared with those without these risk factors. From a total sample size of 128
(n = 7), the pooled prevalence of HBeAg among HBV-infected pregnant women was
14.59% (95% CI = 4.58–27.99%; I2 = 65.5%, p = 0.01). Subgroup analyses of HBV infection
by study region and screening method, and meta-regression analysis of the study year,
sample size, and quality rating were not statistically significant.
Conclusions
There is an intermediate endemicity of HBV infection among pregnant women in Nigeria.
Interventions, such as routine antenatal HBV screening, antiviral prophylaxis for eligible
pregnant women, and infant HBV vaccination should be scaled up for the prevention of peri-
natal transmission of HBV infection in Nigeria.
Background
With over 20 million people estimated to be infected with Hepatitis B virus (HBV) infection,
Nigeria has the largest number of people living with HBV infection in sub-Saharan Africa
(SSA) and ranks third after China and India, globally [1]. The 2018 Nigeria HIV/AIDS Impact
and Survey reported the prevalence of HBV among persons aged 15–49 years is 8.6%, with the
prevalence among males (11.1%) about twice that of females (6.1%) [2]. In Nigeria, HBV is the
most common cause of liver cancer [3] and the fourth leading cause of cancer deaths [4].
Nonetheless, it has continued to be a silent epidemic, as most of the people infected are undi-
agnosed and do not access treatment and prevention services [1, 5].
In highly endemic countries in SSA, HBV is commonly acquired through perinatal trans-
mission from HBV-infected mothers [6, 7], particularly those who have a high viral load and/
or are positive for the hepatitis B e antigen (HBeAg) [8–11]. Approximately 370,000 newborns
are perinatally infected with HBV in SSA annually [12]. While HBV infection in adulthood
leads to chronic hepatitis in less than 5% of adults, about 80–90% of persons infected in the
first year of life develop chronic hepatitis [13, 14]. However, perinatal transmission of HBV is
preventable with safe and effective vaccines [15–17]. Hepatitis B vaccine birth-dose
(HepB-BD) reduces the risk of perinatal transmission to 20–30% in infants of hepatitis B e
antigen (HBeAg)-positive mothers and less than 0.5% in those born to HBeAg-negative moth-
ers [12]. Where available, administering hepatitis B immune globulin (HBIG) to the infants
and maternal antiviral therapy can be of additional benefit, particularly if mothers are HBeAg-
positive [12, 18–20]. The effectiveness of HBV vaccines to prevent transmission underpins the
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current efforts to eliminate HBV infection as a public health threat by 2030 globally [21]. In
2016, Nigeria developed a 5-year strategic plan (2016–2020) as a road map to eliminating viral
hepatitis by 2030 [22].
Despite the high burden of HBV in Nigeria, there is no efficient surveillance system for
monitoring and understanding the epidemiology of the infection [22, 23]. Program data are
deficient as pregnant women are not routinely screened for HBV [24, 25] and population-
based serosurveys are not regularly conducted [22, 26, 27]. Accurate estimates of the burden of
HBV in Nigeria, especially among pregnant women, are needed for rational planning of health
services and would allow public-health policymakers to assign sufficient priority and resources
to its management and prevention. In the absence of surveillance data, information from mul-
tiple studies has been used to generate prevalence estimates. In 2014, a meta-analysis of studies
published between 2000 and 2013 in Nigeria estimated the HBV prevalence in pregnant
women as 14.1% (95% confidence interval [CI] = 9.6, 18.6%) from 14 studies [26]. However,
the review focused on women attending antenatal care in health facilities. Furthermore, the
review did not consider the prevalence of HBV by sociodemographic characteristics, the risk
factors associated with HBV, and the prevalence of HBeAg among HBV-infected pregnant
women. Similar limitations were present in the 2018 national household survey among a pop-
ulation of 435 pregnant women in Nigeria [2].
Since the systematic review and meta-analysis on the prevalence of HBV, including preg-
nant women, in Nigeria, was published seven years ago [26], several studies have become avail-
able. Estimates from these studies may differ from older studies, considering the recent efforts
to eliminate perinatal HBV transmission [22]. Accordingly, this systematic review aimed to
provide expanded up-to-date evidence on the epidemiology of HBV among pregnant women
in Nigeria. The objectives were to determine: (i) the prevalence of HBV infection among preg-
nant women, (ii) the differences in the prevalence of HBV by sociodemographic characteristics
and by known risk factors associated with HBV infection among pregnant women, and (iii)
the prevalence of HBeAg among HBV-infected pregnant women in Nigeria.
Methods
Design
This study was performed and reported using the guidelines for Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [28]. The protocol for this review was
guided by previous reviews and meta-analyses on the epidemiology of HBV among pregnant
women [29–31].
Search strategy
We systematically searched PubMed, Embase, Global Health, and Scopus for eligible articles
published between January 1, 2014 and February 4, 2021. Our search terms included keywords
relating to: “Hepatitis B”, “Pregnancy”, and “Nigeria” (see S1 File for search strategy for
PubMed). We also searched the African Journal Online and manually scanned reference lists
of the identified studies for potentially eligible articles. We restricted our search to studies pub-
lished in English language. We defined HBV infection as a positive test result to hepatitis B
surface antigen (HBsAg) based on a rapid diagnostic test (RDT), enzyme-linked immunosor-
bent assay (ELISA), or both. The sociodemographic characteristics considered included: age
(young pregnant women (<25 years) vs older pregnant women (�25 years)), educational
attainment (none or primary education vs secondary or higher education), monthly income
(below minimum wage (<₦30,0000) vs minimum wage or above (�₦30,000)), religion
(Christianity vs Islam), and any other sociodemographic characteristics reported in at least
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two papers. The known risk factors for HBV considered were previous surgery, blood transfu-
sion, scarification, tribal marks, multiple sex partners, and any other risk factors reported in at
least two papers.
Inclusion and exclusion criteria
We considered both experimental and observational quantitative research studies published in
peer-reviewed journals. Articles were eligible to be included in this study if they were con-
ducted in Nigeria, screened pregnant women for HBV, reported the prevalence of HBsAg and/
or HBeAg among HBsAg-positive women, and/or the prevalence of HBsAg by sociodemo-
graphic characteristics or known risk factors associated with HBV infection. We excluded
studies that did not include pregnant women or did not disaggregate data for pregnant
women. Studies were also excluded if the diagnosis of HBV infection was not based on HBsAg
positive test or not described. Studies that used the same data were also excluded, retaining the
one with more information regarding the inclusion criteria. We excluded studies deemed to
be published in questionable, scholarly open-access (predatory) journals, using a guide by
Ross-White and colleagues [32].
Study selection and abstraction
The study selection was conducted in phases based on the inclusion and exclusion criteria.
Two authors (BOO and DAA) independently screened the titles and abstracts of the articles.
The full articles of those deemed eligible were retrieved and independently screened by the
two authors. At each phase of the screening, we ensured there was an agreement between the
two authors on the selected articles, and cases of conflict were resolved by a third author
(OAO). The data from the included studies were extracted using a pretested tool developed by
the authors (S2 File). Two authors (BOO and OAO) retrieved information including, the first
author’s surname, publication year, study location, study design, study year, the HBV-specific
antigen reported, screening method, number of pregnant women screened for HBV (HBsAg),
number of screened pregnant women who tested positive for HBV (HBsAg), HBV status by
sociodemographic characteristics, the number of HBV-infected women who tested positive for
HBeAg, and the reported risk factors. Where required, authors of the included studies were
contacted for additional information. Two other authors (DAA and EEE) randomly selected
and cross-checked the extracted data.
Quality assessment
The quality of the papers included in the study was assessed by two authors (BOO and OAO)
using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence
Data [33]. The checklist assesses the methodological quality of prevalence studies based on
nine questions (S2 File). Possible responses were ‘yes’; ‘no’; ‘unclear’; or ‘not applicable’. We
assigned a maximum score of 1 to each question, with a potential minimum score of 0 and a
maximum of 9. However, it was decided a priori not to exclude any study based on the quality
rating.
Analysis
We pooled the prevalence of HBV in the studies using the procedure for binomial data [34].
The prevalence of HBV by sociodemographic and known risk factors were compared using
relative risk, referred to as prevalence ratio (PR) in this study. The HBV prevalence and the PR
were estimated using a random-effects meta-analysis model with Freeman-Tukey double
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arcsine transformation [35] and DerSimonian and Laird method [36], respectively. Statistical
heterogeneity was assessed by the Cochran’s Q statistic, with p-value <0.1 as the level of statis-
tical significance [37]. It was further assessed with I2 statistic which shows the percentage of
the variability in pooled estimates that is due to heterogeneity rather than chance [37]. We
considered I2 statistic values of 50% or more as substantial heterogeneity [38]. For HBV preva-
lence, subgroup analyses were performed to identify the possible sources of heterogeneity and
also for group comparison. The studies were grouped by study region and screening methods.
Meta-regression was also performed to assess the effect of the study sample size, year of study,
and quality rating [39]. Publication bias was assessed visually with a funnel plot and using
Egger tests, with a p-value <0.05 considered statistically significant [40]. The meta-analysis
was conducted using STATA V.16.0 for Windows (Stata Statistical Software: Release 16. Col-
lege Station, TX: StataCorp LLC).
Results
Search results
Fig 1 shows the PRISMA flow diagram for study selection. A total of 144 studies were identi-
fied through the four databases with an additional 14 identified from other sources. After the
removal of duplicates, the titles and abstracts of 88 articles were screened, out of which 45 were
found irrelevant. The full-text articles of 43 studies were retrieved and assessed for eligibility.
Twenty articles were included in the meta-analysis and 23 articles were excluded with reasons
illustrated in Fig 1.
The characteristics of the included studies are summarized in Table 1. The publication year
of the included studies ranged from 2014 to 2021. The studies included had a total sample size
Fig 1. PRISMA flow diagram of the process of study identification and selection.
https://doi.org/10.1371/journal.pone.0259218.g001
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of 26, 548. Seventeen of the 20 studies (85%) were facility-based cross-sectional studies [41–
57], two studies were retrospective chart reviews [58, 59], and one was a community-based
cross-sectional study [60]. Half of the studies were conducted in the Northern region (North
Central = 5; North East = 2; and North West = 3) [41–44, 46, 52, 54, 56, 57, 60] and the remain-
ing 50% were conducted in the Southern region (South East = 1 and South West = 9) [45, 47–
50, 53, 55, 58, 59]. HBsAg status was reported in all of the 20 studies, however, only seven stud-
ies [41, 42, 50, 52–55] reported both HBsAg and HBeAg status. HBsAg test was performed
with a rapid diagnostic test (RDT) in eight studies [44, 46, 47, 49, 54, 57, 59, 60], while
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Adeogun, 2020 [48] NS Facility-based cross-sectional
survey





Adeyemi, 2014 [51] 2011 Facility-based cross-sectional
survey
628 South South West (Oyo) ELISA HBsAg 7
Aluor, 2016 [52] 2012 Facility-based cross-sectional
survey







Anaedobe, 2015 [53] 2013 Facility-based cross-sectional
survey
180 South South West (Oyo) ELISA HBsAg and
HBeAg
6
Erhabor, 2020 [54] 2015 Facility-based cross-sectional
survey





Ifeorah, 2017 [55] 2012 Facility-based cross-sectional
survey
272 South South West (Oyo) ELISA HBsAg and
HBeAg
4
Ikeako, 2014 [58] 2006 Retrospective chart review 1239 South South East
(Enugu)
ELISA HBsAg 7
Jibrin, 2016 [56] 2012 Facility-based cross-sectional
survey





Magaji, 2021 [57] 2017 Facility-based cross-sectional
survey
3238 North North Central
(Plateau)
RDT HBsAg 7
Mustapha, 2020 [43] 2018 Facility-based cross-sectional
survey
210 North North East
(Bauchi)
ELISA HBsAg 8
Nongo, 2016 [44] 2012 Facility-based cross-sectional
survey
200 North North Central
(FCT)
RDT HBsAg 4
Ojo, 2016 [59] 2013 Retrospective chart review 373 South South West
(Ondo)
RDT HBsAg 5
Oluremi, 2020 [45] 2019 Facility-based cross-sectional
survey
904 South South West (Oyo) ELISA HBsAg 5
Omatola, 2019 [46] 2017 Facility-based cross-sectional
survey
200 North North Central
(Kogi)
RDT HBsAg 7
Opaleye, 2016 [47] 2014 Facility-based cross-sectional
survey
182 South South West
(Osun)
RDT HBsAg 5
Osho, 2019 [49] 2015 Facility-based cross-sectional
survey
1758 South South West
(Ondo)
RDT HBsAg 5
Talla, 2021 [60] 2017 Community-based cross-
sectional survey
10167 North North Central
(Benue)
RDT HBsAg 8
ELISA: Enzyme-linked immunosorbent assay; RDT: Rapid diagnostic test; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; NS: Not stated
https://doi.org/10.1371/journal.pone.0259218.t001
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enzyme-linked immunosorbent assay (ELISA) was used in six studies [43, 45, 51, 53, 55, 58].
Six studies used RDT as the initial test and ELISA as the confirmatory test [41, 42, 48, 50, 52,
56]. ELISA was used to test for HBeAg in all the seven studies that assessed it [41, 42, 50, 52–
55]. The methodological quality score was� 7 in eight studies [43, 46, 50–52, 57, 58, 60], while
the other twelve studies scored between 4 and 6 [41, 42, 44, 45, 47–49, 53–56, 59].
HBV prevalence
The HBV prevalence in the 20 studies included in the meta-analysis ranged from 1.00% to
14.87% (Fig 2). Out of the 20 studies, only five studies reported a prevalence of more than 8%.
The pooled prevalence of HBV among pregnant women in the 20 studies was 6.49% (95% con-
fidence interval [CI] = 4.75–8.46%; I2 = 96.7%, p = 0.001) (Fig 2).
HBV prevalence and prevalence ratios by sociodemographic characteristics
and risk factors
The HBV prevalence varied by sociodemographic characteristics and known risk factors
(Table 2). The results indicated a significantly lower prevalence of HBV in pregnant women
who had at least secondary education compared with those who had primary or no education
(PR = 0.71, 95% CI = 0.58–0.87). However, the prevalence of HBV was not significantly differ-
ent by age, religion, marital status, or tribe (Table 2). Similarly, the prevalence of HBV was not
significantly different among pregnant women with previous surgery (PR = 1.08, 95%
CI = 0.90–1.29), blood transfusion (PR = 1.19, 95% CI = 0.95–1.48), multiple lifetime sex part-
ners (PR = 0.80, 95% CI = 0.35–1.82), tattoos (PR = 1.02, 95% CI = 0.72–1.45), tribal marks
(PR = 0.19, 95% CI = 0.02–1.45), scarification (PR = 0.87, 95% CI = 0.38–2.02), or sexually
transmitted infections (PR = 1.05, 95% CI = 0.62–1.78).
Prevalence of HBeAg
Seven studies with a total sample size of 128 reported the prevalence of HBeAg among preg-
nant women who had HBV infection. The prevalence ranged from 0% to 36.67% (Fig 3). The
pooled prevalence of HBeAg across the seven studies was 14.59% (95% CI = 4.58–27.99%, I2 =
65.5%, p = 0.01).
Subgroup analysis
Table 3 (S4 File) shows the subgroup analyses of HBV prevalence based on the region and
screening method. The HBV prevalence in the North was 7.61% (95%CI = 5.56–9.95%), while
the prevalence in the South was 5.38% (95% CI = 3.84–7.16%) (p-value of difference = 0.104).
There was no difference in the prevalence by RDT and ELISA (6.85%; 95% CI = 2.20–13.74%),
ELISA only (5.81%; 95% CI = 4.24–7.59%), and RDT only (6.63% (95% CI = 4.59–8.49%) (p-
value of difference = 0.808). The findings suggest that the study region and screening method
used were not the sources of heterogeneity.
Meta-regression
The meta-regression model showed no statistically significant association between the sample
size of the studies and HBV prevalence (p = 0.282) (S5 File). Similarly, the association between
the study year and HBV prevalence was not statistically significant (p = 0.638) (S5 File). The
quality rating of the studies was also not significant (p = 0.470) (S5 File). The findings suggest
that none of these variables was the source of heterogeneity.
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Publication bias
The funnel plot of the studies included in the review suggests no publication bias (Fig 4). The
absence of publication bias was further confirmed by the Eggers test (p = 0.778).
Discussion
To extend the growing body of evidence on HBV in Nigeria, we conducted a systematic review
and meta-analysis of the prevalence of HBV among pregnant women using studies published
between January 2014 and February 2021. The pooled prevalence of HBV among pregnant
women across the 20 studies included in this review was 6.49%. The prevalence of HBV was
significantly lower among pregnant women with at least secondary education compared with
those with no education or primary education. However, the prevalence of HBV was not sig-
nificantly different by age, religion, marital status, or tribe. The prevalence of HBV was also
not significantly different by known risk factors such as pregnant women with previous sur-
gery, blood transfusion, multiple lifetime sex partners, tribal marks, tattoos, scarification, or
Fig 2. Forest plot of HBV prevalence among pregnant women in Nigeria, 2014–2021.
https://doi.org/10.1371/journal.pone.0259218.g002
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� 25 years 6 4436 160 5.28% (3.13–7.93%) 1.37 (0.89–2.11) 0.158
<25 years 6 1062 26 2.86% (0.85–5.72%)
Educational attainment
Secondary or higher 10 3398 330 7.11% (4.30–10.49%) 0.71 (0.58–0.87) <0.001
None or primary 10 1567 196 6.49% (1.94–12.67%)
Religion
Christianity 3 345 28 8.10% (5.38–11.29%) 1.27 (0.65–2.51) 0.483
Islam 3 175 11 6.24% (2.94–10.51%)
Marital Status
Married 6 4644 307 5.45% (3.42–7.91%) 0.65 (0.32–1.31) 0.233
Unmarrieda 6 106 6 1.72% (0.00–9.04%)
Tribe
Yoruba 3 239 17 5.59% (2.59–9.37%) 0.79 (0.24–2.60)b 0.697
Igbo 3 54 3 2.26% (0.00–10.54%) 1.08 (0.33–3.53)c 0.894
Hausa 3 137 18 10.93% (5.49–17.55%) 0.61 (0.20–1.92)d 0.401
Risk factors
Surgery
Yes 6 1296 130 7.67% (3.65–12.84%) 1.08 (0.90–1.29) 0.409
No 6 5734 536 6.42% (3.12–10.75%)
Blood transfusion
Yes 8 652 77 7.11% (2.67–12.99%) 1.19 (0.95–1.48) 0.121
No 8 6802 634 7.53% (4.51–11.23%)
Multiple lifetime sex
partnerse
Yes 3 464 22 4.50% (2.71–6.68%) 0.80 (0.35–1.82) 0.603
No 3 726 38 6.79% (2.49–12.83%)
Tattoos
Yes 3 448 33 3.99% (0.61–9.14%) 1.02 (0.72–1.45) 0.901
No 3 3172 238 7.38% (6.48–8.33%)
Tribal marks
Yes 2 137 0 0.00% (0.00–1.01%) 0.19 (0.02–1.45) 0.108
No 2 245 15 5.73% (3.07–9.08%)
Scarification
Yes 3 849 107 5.05% (0.00–19.07%) 0.87 (0.38–2.02) 0.754
No 3 2853 303 8.14% (3.26–14.91%)
Sexually transmitted
infections
Yes 5 288 15 3.76% (0.98–7.69%) 1.05 (0.62–1.78) 0.851
No 5 1384 76 5.48% (2.72–9.08%)
a Unmarried includes single and divorced;
bYoruba vs Igbo;
c Igbo vs Hausa;
dYoruba vs Hausa
e Multiple lifetime sex partners: Defined as more than 1 lifetime sexual partner
https://doi.org/10.1371/journal.pone.0259218.t002
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sexually transmitted infections. Among HBV-infected pregnant women, the pooled prevalence
of HBeAg was 14.59%.
As a result of the expanded HBV vaccination program, the prevalence of HBV infection has
decreased, globally but remains highly endemic in some regions, including Africa [61]. Going
by the definition of HBV endemicity based on the HBsAg prevalence: low (<2%), lower-inter-
mediate (2–4.99%), higher intermediate (5–7.99%), and high (>8%) [61], our results indicate
higher-intermediate endemicity of HBV infection among pregnant women in Nigeria. In line
with the World Health Organization (WHO) recommendations [62], Nigeria currently offers
a HepB-BD in the national immunization program for children, followed by 3 doses to com-
plete the primary series [24, 63]. HBV vaccination is also recommended for the prevention of
Fig 3. Forest plot of HBeAg prevalence among HBV-infected pregnant women in Nigeria.
https://doi.org/10.1371/journal.pone.0259218.g003
Table 3. Subgroup analysis of HBV prevalence among pregnant women in Nigeria, 2014–2021.
Subgroups Number of studies Number of participants Pooled prevalence (95% CI) I2 (p-value) P-value (subgroup differences)
Region
North 10 17864 7.61% (5.56–9.95%) 94.7% (<0.001) 0.104
South 10 8684 5.38% (3.84–7.16%) 87.0% (<0.001)
Screening method
RDT and ELISA 6 6880 6.85% (2.20–13.74%) 98.6% (<0.001) 0.808
ELISA 6 3433 5.81% (4.24–7.59%) 73.3% (<0.001)
RDT 8 16235 6.63% (4.59–8.49%) 94.4% (<0.001)
https://doi.org/10.1371/journal.pone.0259218.t003
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HBV in older children, adolescents, and adults, including high-risk populations such as sex
workers, medical personnel, and drivers [63]. However, the coverage of HBV vaccines remains
suboptimal. The reported estimates of HepB-BD and Hepatitis B 3rd dose (HepB3) coverage in
2019 were 52% and 57%, respectively [64]. Low uptake of HBV vaccines has also been reported
among at-risk populations such as health care providers [65, 66]. Several factors, including
limited maternal knowledge and unawareness of HBV, unavailability of HBV vaccine, child
delivery outside formal health facilities, a long distance from the health facility, and high cost
of vaccination, affect the uptake of HBV vaccination in Nigeria [65–69]. Reducing the burden
of HBV will require addressing these barriers limiting the vaccination coverage.
The pooled prevalence of HBV in our study compares with the 2018 national household
survey in Nigeria that reported a prevalence of 5.9% and among pregnant women [2]. How-
ever, it is nearly half of the 14.1% reported in a previous meta-analysis of studies published
from 2000–2013 [26]. While the reason for the wide disparity is not clear, this result may sug-
gest a decline in HBV prevalence among pregnant women in Nigeria. Trend studies are
needed to examine how the prevalence of HBV infection has changed in Nigeria since the
commencement of the vaccination program in 2004. It is noteworthy that the prevalence of
HBV was not significantly different by sociodemographic characteristics except educational
attainment. Educated women are more likely to be aware of HBV and to have been vaccinated
against HBV [70]. This may explain the significant lower prevalence among those who had at
least secondary education compared with less-educated women.
Horizontal transmission from infected blood and bodily fluids is a common source of HBV
infection in Africa [63, 71–73]. However, in this review, there was insufficient evidence to sug-
gest that the risk factors for horizontal transmission such as previous surgery, blood transfu-
sion, multiple lifetime sex partners, tribal marks, tattoos, scarification, or sexually transmitted
infections were associated with HBV among pregnant women in Nigeria. Previous studies
have also reported similar results with previous surgery [29, 74], tattooing [29], blood
Fig 4. Funnel plot of included studies.
https://doi.org/10.1371/journal.pone.0259218.g004
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transfusion [29, 74–76], scarification [76], and multiple sex partners [74, 76] among pregnant
women. Improvement in blood transfusion safety could have contributed to the reduction in
the iatrogenic transmission of HBV infection [77]. Importantly, these findings support a previ-
ous recommendation that risk-based HBV screening of pregnant women may not be effective
in Nigeria [73]. Household contact is another important source of horizontal transmission
that may be responsible for the high burden of HBV among pregnant women [74]. Although
the mechanism of household contact transmission of HBV is not fully understood, sharing of
personal and household items has been implicated [78–80]. Consequently, contact tracing and
screening of household contacts is important in limiting infection spread and should be better
incorporated into HBV management protocols in Nigeria.
In this review, we found a high prevalence of HBeAg among HBV-infected pregnant
women. Even though HBeAg is not as prevalent in Africa as other high endemic regions [81],
it remains a critical risk factor in the perinatal transmission of HBV in the region [12]. Where
viral load tests for HBV DNA quantification are not accessible or affordable, HBeAg positive
test can be used as a proxy for high HBV DNA among pregnant women [82, 83], which is an
indication for additional interventions such as antiviral (tenofovir disoproxil fumarate [TDF])
prophylaxis [82]. TDF prophylaxis, however, is not widely accessible to HBV-infected women
in Nigeria, except for those who are co-infected with HIV and may be receiving TDF-based
ART through the HIV program [84]. Our findings highlight the need for pregnant women
who test positive for HBV in Nigeria to undergo further serological tests to determine their
risk of transmission and the appropriate interventions. The availability of reliable and low-cost
rapid test kits for HBeAg may improve access to this test in resource-constrained settings [85].
Access to antiviral therapy among HBeAg-positive women should also be prioritized by the
government and donor partners.
This review is not without limitations. We considered four databases and might have
missed articles in databases not considered. Moreover, many of the studies did not report on
the prevalence of HBsAg by sociodemographic characteristics or the prevalence of HBeAg.
The differences in the description and categorization of some variables prevented the inclusion
of some studies in the meta-analyses. We had planned to assess the difference between HBV
prevalence from facility-based and community-based studies. However, we only found one
community-based study. More community-based studies are needed on HBV prevalence, con-
sidering that many women do not attend health facilities for ANC. Future review studies on
the epidemiology of HBV pregnant women in Nigeria should consider extending our findings
on the prevalence of HBeAg or assessing HBV DNA levels. Evidence is also required on the
rate of perinatal transmission among HBV-infected pregnant women in Nigeria. Although
there was an even North-South divide among included studies, future research which focuses
on the zones with limited studies may also be warranted.
Conclusions
There is an intermediate endemicity of HBV infection among pregnant women in Nigeria. As
Nigeria continues in its effort to eliminate HBV infection, interventions including routine
antenatal HBV screening, antiviral prophylaxis for eligible pregnant women, HBIG, and uni-
versal infant vaccination which includes HepB-BD need to be strengthened for the prevention
of perinatal transmission of HBV infection.
Supporting information
S1 File. Search strategy for PubMed.
(DOCX)
PLOS ONE Hepatitis B prevalence among pregnant women in Nigeria
PLOS ONE | https://doi.org/10.1371/journal.pone.0259218 October 29, 2021 12 / 17
S2 File. Data abstraction form and quality assessment tool.
(DOCX)
S3 File. Forest plots of HBV prevalence ratio by sociodemographic characteristics and risk
factors.
(DOCX)
S4 File. Forest plots of HBV prevalence by study region and screening method.
(DOCX)
S5 File. Bubble plots of meta-regression of HBV prevalence against sample size, quality





Conceptualization: Babayemi O. Olakunde, Daniel A. Adeyinka, Echezona E. Ezeanolue.
Data curation: Babayemi O. Olakunde, Daniel A. Adeyinka, Olubunmi A. Olakunde, Eche-
zona E. Ezeanolue.
Formal analysis: Babayemi O. Olakunde, Olalekan A. Uthman.
Writing – original draft: Babayemi O. Olakunde, Daniel A. Adeyinka, Olubunmi A.
Olakunde.
Writing – review & editing: Babayemi O. Olakunde, Olalekan A. Uthman, Florence O. Bada,
Yvonne A. Nartey, Dorcas Obiri-Yeboah, Elijah Paintsil, Echezona E. Ezeanolue.
References
1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al. Global preva-
lence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastro-
enterol Hepatol. 2018; 3: 383–403. https://doi.org/10.1016/S2468-1253(18)30056-6 PMID: 29599078
2. Federal Ministry of Health. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018: Final report.
Abuja; 2019.
3. Yang JD, Mohamed EA, Aziz AOA, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics, man-
agement, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observa-
tional study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017; 2(2):103–
11. https://doi.org/10.1016/S2468-1253(16)30161-3 PMID: 28403980
4. International Agency for Research on Cancer. Nigeria. https://gco.iarc.fr/today/data/factsheets/
populations/566-nigeria-fact-sheets.pdf. (2019). Accessed May 4, 2021.
5. Abutu A. Nigeria’s complicated hepatitis burden. Lancet Gastroenterol Hepatol. 2018; 3(10):669.
6. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and preven-
tion in developing countries. World J Hepatol. 2012; 4(3):74–80. https://doi.org/10.4254/wjh.v4.i3.74
PMID: 22489259
7. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005; 2
(1):50–7. https://doi.org/10.7150/ijms.2.50 PMID: 15968340
8. Xu D-Z, Yan Y-P, Choi BCK, Xu J-Q, Men K, Zhang J-X, et al. Risk factors and mechanism of transpla-
cental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002; 67(1):20–6. https://doi.
org/10.1002/jmv.2187 PMID: 11920813
9. Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and
HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through
PLOS ONE Hepatitis B prevalence among pregnant women in Nigeria
PLOS ONE | https://doi.org/10.1371/journal.pone.0259218 October 29, 2021 13 / 17
the placenta and the rate of decay in babies. J Med Virol. 2003; 71(3):360–66. https://doi.org/10.1002/
jmv.10493 PMID: 12966540
10. Burk RD, Hwang LY, Ho GYF, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis b virus exposure
is dependent on maternal virus load. J Infect Dis. 1994; 170(6):1418–23. https://doi.org/10.1093/infdis/
170.6.1418 PMID: 7995980
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